Last reviewed · How we verify
NCT04807348
Chiglitazar Added to Metformin for Type 2 Diabetes
Phase 3 trial testing Chiglitazar 32mg in Type 2 Diabetes in 533 participants. Completed in 10 February 2023.
10 February 2023
Quick facts
| Lead sponsor | Chipscreen Biosciences, Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 533 |
| Start date | 6 July 2021 |
| Primary completion | 10 February 2023 |
| Estimated completion | 10 February 2023 |
| Sites | 50 locations across China |
Drugs / interventions tested
- Chiglitazar 32mg — full drug profile →
- Chiglitazar 48mg — full drug profile →
- Placebo
- Metformin Hydrochloride — full drug profile →
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Chipscreen Biosciences, Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel Therapeutics for Type 2 Diabetes Mellitus-A Look at the Past Decade and a Glimpse into the Future.
Chee YJ, Dalan R. · · 2024 · cited 3× · PMID 39061960 · DOI 10.3390/biomedicines12071386 -
Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study).
Gao L, Ji L, Yan X, Cheng Z, et al · · 2025 · cited 1× · PMID 40842343 · DOI 10.1111/dom.70009
Verify or expand the search:
- PubMed search for NCT04807348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Chipscreen Biosciences, Ltd. trials
Trials by the same sponsor.
- NCT07511010 — Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets · Phase 1 · not yet recruiting
- NCT07519265 — Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
- NCT07412015 — Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
- NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
- NCT07129382 — A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04807348 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chipscreen Biosciences, Ltd.
- Last refreshed: 15 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04807348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing